8-K: Turning Point Brands Q1 2026: Modern Oral Drives Growth

Turning Point Brands reported a 16.8% increase in Q1 2026 net sales to $124.3 million, primarily driven by a 133% surge in Modern Oral net sales, which now constitute 42% of total sales.

Summary

• Total consolidated net sales for the first quarter of 2026 increased by 16.8% to $124.3 million compared to the prior year.
• Modern Oral net sales saw a significant increase of 133%, reaching $52.0 million and representing 42% of total company net sales, up from 21% in Q1 2025.
• The Stoker's segment experienced a net sales increase of 48.1% to $87.6 million.
• The Zig-Zag segment's net sales decreased by 22.4% to $36.7 million, attributed to lower U.S. papers and wraps shipments.
• Gross profit increased by 14.6% to $68.3 million.
• Net income decreased by 19.0% to $11.7 million.
• Adjusted EBITDA decreased by 6.5% to $25.9 million.
• Diluted EPS was $0.60, and Adjusted Diluted EPS was $0.76, down from $0.79 and $0.91 respectively in the prior year.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed result; while top-line growth and Modern Oral segment performance are strong positives, the decline in net income, Adjusted EBITDA, and EPS, coupled with a significant increase in SG&A, temper the overall sentiment.

Positives

• Strong momentum in the Modern Oral segment, with net sales increasing 133% to $52.0 million and now representing 42% of total company net sales.
• Stoker's segment net sales increased by a robust 48.1%.
• Total consolidated net sales grew by 16.8% to $124.3 million.
• Gross profit increased by 14.6% to $68.3 million.
• Company is raising its full-year 2026 guidance for Modern Oral Gross Sales and Net Sales.
• Introducing full-year 2026 Adjusted EBITDA guidance of $70-$90 million.
• Ending cash balance of $192.4 million and total liquidity of $265.0 million provide a strong financial position.

Negatives

• Net income decreased by 19.0% to $11.7 million.
• Adjusted EBITDA decreased by 6.5% to $25.9 million.
• Diluted EPS decreased to $0.60 from $0.79 in the prior year.
• Adjusted Diluted EPS decreased to $0.76 from $0.91 in the prior year.
• Zig-Zag segment net sales decreased by 22.4% due to lower U.S. papers and wraps shipments.
• Consolidated selling, general, and administrative (SG&A) expenses increased significantly by 53.2% to $55.8 million, driven by Modern Oral investments and increased freight costs.

Risks

• The decrease in Zig-Zag segment net sales due to lower U.S. papers and wraps shipments could continue if market conditions do not improve.
• Increased SG&A expenses related to Modern Oral investments and freight costs could impact profitability if not managed effectively.
• The company's reliance on the evolving nicotine consumption market presents inherent risks and uncertainties.
• Future results may differ materially from forward-looking statements due to various risks and uncertainties detailed in SEC filings.

Future Outlook

The company is raising its full-year 2026 guidance for Modern Oral Gross Sales to $280-$300 million (from $220-$240 million) and Modern Oral Net Sales to $210-$225 million (from $180-$190 million). Additionally, the company is introducing full-year 2026 Adjusted EBITDA guidance of $70-$90 million, which includes investments in Modern Oral sales, marketing, and trade promotions.

Management Comments

• "We delivered a strong first quarter, driven by continued momentum in Modern Oral and disciplined execution across the portfolio," said Graham Purdy, President and CEO.
• "We believe we are in the early stages of a generational shift in nicotine consumption, with significant opportunity ahead as the category continues to evolve."
• "We are investing behind our brands, commercial capabilities, and consumer reach to position us to capture meaningful share in white pouch, including through initiatives such as our recently announced TKO partnership featuring UFC."
• "At the same time, our legacy brands continue to generate strong cash flow, providing the foundation to fund our strategic priorities."
• "We remain confident in our ability to scale our modern oral business and drive long-term value for shareholders."

Industry Context

StockSavvy.ai notes that Turning Point Brands' significant growth in its Modern Oral segment aligns with broader industry trends of shifting consumer preferences towards alternative nicotine products. The company's strategic investments in this area, including partnerships, indicate a proactive approach to capturing market share in a rapidly evolving sector.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through scaling the modern oral business, but short-term concerns due to decreased net income and EPS.
• Employees: Increased investment in sales and marketing may lead to expanded commercial teams.
• Suppliers: Increased demand from Modern Oral growth may impact supply chain operations.
• Creditors: Stable liquidity and net debt position provide some assurance, but declining profitability could be a concern.

Next Steps

• Continue investing in brands, commercial capabilities, and consumer reach to capture share in the white pouch market.
• Leverage strong cash flow from legacy brands to fund strategic priorities.
• Scale the modern oral business to drive long-term shareholder value.
• Hold a conference call on May 7, 2026, at 8:30 a.m. Eastern to discuss financial results.

Key Dates

Recommendation

The company shows strong growth in a key strategic area (Modern Oral) and is raising guidance for it, which is positive. However, the reported decrease in net income, Adjusted EBITDA, and EPS, alongside a substantial increase in SG&A expenses, indicates current profitability challenges that warrant a cautious 'hold' rating until these trends stabilize or improve.

Keywords

Turning Point Brands, TPB, 8-K, Q1 2026 Results, Modern Oral, Stoker's, Zig-Zag, Financial Results